Anxiety and depressive disorders are common in the pediatric primary care setting, and respond to both psychotherapeutic and psychopharmacologic treatment. However, there are limited data regarding the optimal treatment duration. This article systematically reviews guidelines and clinical trial data related to antidepressant treatment duration in pediatric patients with depressive and anxiety disorders. The extant literature suggests 9–12 months of antidepressant treatment for youth with major depressive disorder. For generalized, separation and social anxiety disorders, 6–9 months of antidepressant treatment may be sufficient, though many clinicians extend treatment to 12 months based on extrapolation of data from adults with anxiety disorders. Such extended treatment periods may decrease the risk of long-term morbidity and recurrence; however, the goal of treatment is ultimately remission, rather than duration of antidepressant pharmacotherapy. Moreover, while evidence-based guidelines represent a starting point, appropriate treatment duration varies and patient-specific response, psychological factors, and timing of discontinuation must be considered for individual pediatric patients.
|Original language||English (US)|
|Number of pages||9|
|Journal||Current Problems in Pediatric and Adolescent Health Care|
|State||Published - Feb 2018|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health